Literature DB >> 10550730

Immunostimulatory DNA and applications to allergic disease.

J Van Uden1, E Raz.   

Abstract

The vertebrate immune system reacts to certain sequences of DNA with a strong T(H)1-inducing innate response. These sequences, termed immunostimulatory DNA sequences, are not fully defined but generally consist of a central nonmethylated CG dinucleotide, flanked by less highly conserved sequences (hence the alternate name CpG motifs). These sequences seem to be rare in vertebrates but relatively common in many lower organisms, including bacteria and viruses. It is likely that these sequences represent a danger signal to the immune system; a powerful T(H)1 response is induced against colocalized foreign antigen. This can be used to modify an allergic response away from a pathogenic T(H)2-dominated immune profile toward a nonpathogenic and even protective T(H)1 profile.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550730     DOI: 10.1016/s0091-6749(99)70066-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

Review 1.  Introduction to immunostimulatory DNA sequences.

Authors:  J Van Uden; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA.

Authors:  Ana-Maria Dragoi; Xiaoying Fu; Stanimir Ivanov; Ping Zhang; Linbo Sheng; Dianqing Wu; Gloria C Li; Wen-Ming Chu
Journal:  EMBO J       Date:  2005-01-27       Impact factor: 11.598

4.  Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.

Authors:  Alexander H Dalpke; Stefan Zimmermann; Inka Albrecht; Klaus Heeg
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

5.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.